The U.S. Food and Drug Administration (FDA) has issued a warning letter to Novo Nordisk, the Danish pharmaceutical giant, citing serious violations related to the reporting of adverse events associated with its popular drugs Wegovy, Ozempic, and Victoza. The warning, issued on September 9, 2025, stems from an inspection of Novo Nordisk’s Plainsboro, New Jersey facility and raises concerns about the company’s compliance with federal regulations regarding drug safety reporting.
The FDA’s concerns center around procedures that led to failures in reporting suspected side effects, a critical component of ensuring patient safety and monitoring the long-term effects of medications. This isn’t simply a procedural oversight; the agency explicitly stated it has “serious concerns about the scope and impact of these violations on your entire product portfolio.” The issues were initially identified during an inspection that began in early 2025, as detailed in the FDA’s warning letter.
Novo Nordisk’s medications – Wegovy (semaglutide) for weight management, Ozempic (semaglutide) for type 2 diabetes, and Victoza (liraglutide) as well for type 2 diabetes – have experienced significant demand in recent years, particularly Wegovy, fueled by growing awareness of obesity as a chronic health condition and high-profile endorsements. The FDA’s scrutiny comes at a sensitive time for the company, as it navigates increasing competition in the weight loss market and works to maintain public trust in its products. The agency’s letter specifically references a direct-to-consumer video, “An Oprah Special: Shame, Blame, and the Weight Loss Revolution,” featuring paid consultants who receive research funding from companies developing GLP-1 drugs, and a senior vice president of cardiometabolic sales for Novo Nordisk.
FDA Cites Misleading Promotion and Reporting Failures
The FDA’s warning letter doesn’t solely focus on adverse event reporting. It also alleges that the promotional video featuring Oprah Winfrey contained false or misleading information, effectively misbranding Wegovy, Ozempic, and Victoza. The agency’s assessment indicates that the video’s presentation of the drugs and the involvement of paid consultants raise questions about objectivity and transparency. The video originally aired on ABC as a Primetime Oprah Special on March 18, 2024, and was subsequently available on Hulu from March 19, 2024, amplifying its reach.
Specifically, the FDA took issue with the presence of Dr. W. Scott Butsch and Dr. Amanda Velazquez, identified as paid consultants who “receive research funding from companies making GLP-1 drugs.” This financial connection, the FDA argues, wasn’t adequately disclosed, potentially influencing the presentation of information about the drugs. Negelle Morris, Senior Vice President of Cardiometabolic Sales for Novo Nordisk, also appeared in the video, further highlighting the company’s direct involvement in the promotional material.
Beyond the promotional concerns, the core of the FDA’s warning revolves around compliance with 21 CFR 314.81(b)(3)(i), which mandates the submission of promotional materials to the agency at the time of initial dissemination. The FDA states that these materials were not submitted, representing a violation of federal regulations. This requirement is in place to allow the FDA to review promotional content for accuracy and ensure it doesn’t mislead patients or healthcare professionals.
What are Adverse Event Reporting Requirements?
Adverse event reporting is a cornerstone of pharmaceutical safety. It’s a legal requirement for drug manufacturers to promptly report to the FDA any suspected side effects or safety concerns associated with their products. This system, known as MedWatch, allows the FDA to identify potential safety signals, assess risks, and take appropriate action to protect public health. The FDA relies on these reports from manufacturers, healthcare professionals, and consumers to continuously monitor the safety profile of drugs on the market. The FDA’s MedWatch program provides detailed information on how to report adverse events and what types of information are needed.
The specific regulations governing adverse event reporting are outlined in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and related regulations. Violations can result in warning letters, fines, and other enforcement actions. The FDA’s concern in the Novo Nordisk case isn’t simply about isolated incidents but about systemic failures in the company’s procedures for identifying, evaluating, and reporting adverse events. This suggests a potential pattern of non-compliance that could have broader implications for patient safety.
Novo Nordisk’s Response and Potential Consequences
As of Tuesday, March 10, 2026, Novo Nordisk acknowledged receiving the warning letter from the FDA, according to Reuters. The company has not yet released a detailed response outlining specific steps it will take to address the FDA’s concerns. However, it is expected to submit a corrective action plan to the agency outlining how it will rectify the identified violations and ensure future compliance.
The potential consequences of failing to adequately address the FDA’s concerns are significant. The agency could impose financial penalties, require additional inspections, or even halt the production or distribution of affected drugs. The warning letter could damage Novo Nordisk’s reputation and erode public trust in its products. The FDA has the authority to seek injunctions to prevent the distribution of misbranded or adulterated drugs, and in severe cases, can pursue criminal charges.
This situation also comes as Novo Nordisk is awaiting FDA review of CagriSema, a drug for obesity and type 2 diabetes. According to MarketBeat, the drug is currently under review by the FDA, with key regulatory milestones being closely monitored. Any delays or complications arising from the current warning letter could potentially impact the timeline for CagriSema’s approval.
Impact on Patients and Healthcare Providers
While the FDA’s warning letter doesn’t directly impact patients currently taking Wegovy, Ozempic, or Victoza, it underscores the importance of ongoing vigilance and open communication between patients and their healthcare providers. Patients experiencing any unexpected or concerning side effects should promptly report them to their doctor and through the FDA’s MedWatch program. Healthcare providers should remain informed about potential safety concerns and ensure they are providing patients with accurate and unbiased information about these medications.
The FDA’s action serves as a reminder of the rigorous regulatory oversight that pharmaceutical companies are subject to, and the agency’s commitment to protecting public health. It also highlights the importance of transparency in drug promotion and the need for manufacturers to prioritize patient safety above all else. The coming months will be crucial as Novo Nordisk works to address the FDA’s concerns and restore confidence in its commitment to regulatory compliance.
The next step in this process will be Novo Nordisk’s formal response to the FDA, outlining its corrective action plan. The FDA will then review the plan and determine whether it adequately addresses the identified violations. Further updates will likely be provided by the FDA as the situation evolves. Readers are encouraged to share their thoughts and experiences in the comments section below.